Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review

The new drugs delamanid and bedaquiline are increasingly being used to treat multidrug-resistant (MDR-) and extensively drug-resistant tuberculosis (XDR-TB). The World Health Organization, based on lack of evidence, recommends their use under specific conditions and not in combination. No systematic...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences Vol. 18; no. 2; p. 341
Main Authors: Migliori, Giovanni, Pontali, Emanuele, Sotgiu, Giovanni, Centis, Rosella, D’Ambrosio, Lia, Tiberi, Simon, Tadolini, Marina, Esposito, Susanna
Format: Journal Article
Language:English
Published: Switzerland MDPI AG 07.02.2017
MDPI
Subjects:
Antitubercular Agents - therapeutic use
Diarylquinolines - administration & dosage
Diarylquinolines - adverse effects
Diarylquinolines - therapeutic use
Drug resistance
Drug Therapy, Combination
Extensively Drug-Resistant Tuberculosis - diagnosis
Extensively Drug-Resistant Tuberculosis - drug therapy
Extensively Drug-Resistant Tuberculosis - epidemiology
Extensively Drug-Resistant Tuberculosis - microbiology
Humans
Multidrug resistant organisms
Mycobacterium
Nitroimidazoles - administration & dosage
Nitroimidazoles - adverse effects
Nitroimidazoles - therapeutic use
Oxazoles - administration & dosage
Oxazoles - adverse effects
Oxazoles - therapeutic use
Review
Studies
Treatment Outcome
Tuberculosis
Tuberculosis, Multidrug-Resistant - diagnosis
Tuberculosis, Multidrug-Resistant - drug therapy
Tuberculosis, Multidrug-Resistant - epidemiology
Tuberculosis, Multidrug-Resistant - microbiology
effectiveness
safety
tolerability
MDR-TB
delamanid
XDR-TB
bedaquiline
ISSN:1422-0067, 1661-6596, 1422-0067
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract The new drugs delamanid and bedaquiline are increasingly being used to treat multidrug-resistant (MDR-) and extensively drug-resistant tuberculosis (XDR-TB). The World Health Organization, based on lack of evidence, recommends their use under specific conditions and not in combination. No systematic review has yet evaluated the efficacy, safety, and tolerability of delamanid and bedaquiline used in combination. A search of peer-reviewed, scientific evidence was carried out, aimed at evaluating the efficacy/effectiveness, safety, and tolerability of delamanid and bedaquiline-containing regimens in individuals with pulmonary/extrapulmonary disease, which were bacteriologically confirmed as M/XDR-TB. We used PubMed to identify any relevant manuscripts in English up to the 23 December 2016, excluding editorials and reviews. Three out of 75 manuscripts retrieved satisfied the inclusion criteria, whilst 72 were excluded for dealing with only one drug (three studies), being recommendations (one study) or identifying need for their use (one study), focusing on drug resistance aspects (six studies) or being generic reviews/other studies (61 papers). The studies retrieved reported two XDR-TB cases observed for six months and achieving consistent sputum smear and culture conversion. Case 2 experienced a short break of bedaquiline, which was re-started after introducing verapamil. After a transient and symptom-free increase of the QT interval from week 5 to 17, it then decreased below the 500 ms threshold.
AbstractList The new drugs delamanid and bedaquiline are increasingly being used to treat multidrug-resistant (MDR-) and extensively drug-resistant tuberculosis (XDR-TB). The World Health Organization, based on lack of evidence, recommends their use under specific conditions and not in combination. No systematic review has yet evaluated the efficacy, safety, and tolerability of delamanid and bedaquiline used in combination. A search of peer-reviewed, scientific evidence was carried out, aimed at evaluating the efficacy/effectiveness, safety, and tolerability of delamanid and bedaquiline-containing regimens in individuals with pulmonary/extrapulmonary disease, which were bacteriologically confirmed as M/XDR-TB. We used PubMed to identify any relevant manuscripts in English up to the 23 December 2016, excluding editorials and reviews. Three out of 75 manuscripts retrieved satisfied the inclusion criteria, whilst 72 were excluded for dealing with only one drug (three studies), being recommendations (one study) or identifying need for their use (one study), focusing on drug resistance aspects (six studies) or being generic reviews/other studies (61 papers). The studies retrieved reported two XDR-TB cases observed for six months and achieving consistent sputum smear and culture conversion. Case 2 experienced a short break of bedaquiline, which was re-started after introducing verapamil. After a transient and symptom-free increase of the QT interval from week 5 to 17, it then decreased below the 500 ms threshold.
Author D’Ambrosio, Lia
Centis, Rosella
Tiberi, Simon
Migliori, Giovanni
Pontali, Emanuele
Tadolini, Marina
Sotgiu, Giovanni
Esposito, Susanna
AuthorAffiliation 4 Public Health Consulting Group, Lugano CH-6904, Switzerland
6 Unit of Infectious Diseases, Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna 40138, Italy; mtadolini@hotmail.com
7 Pediatric Clinic, Department of Surgical and Biomedical Sciences, Università degli Studi di Perugia, Perugia 06129, Italy
5 Division of Infection, Royal London Hospital, Barts Health NHS Trust, 80 Newark Street, London E1 2ES, UK; simon.tiberi@bartshealth.nhs.uk
3 Clinical Epidemiology and Medical Statistics Unit, Department of Biomedical Sciences, University of Sassari, Sassari 07100, Italy; gsotgiu@uniss.it
1 World Health Organization Collaborating Centre for Tuberculosis and Lung Diseases, Maugeri Institute, IRCCS Tradate 21049, Italy; giovannibattista.migliori@icsmaugeri.it (G.B.M.); rosella.centis@icsmaugeri.it (R.C.); liadambrosio59@gmail.com (L.D.)
2 Department of Infectious Diseases, Galliera Hospital, Genoa 16128, Italy; pontals@yahoo.com
8 Pediatric Highly In
AuthorAffiliation_xml – name: 1 World Health Organization Collaborating Centre for Tuberculosis and Lung Diseases, Maugeri Institute, IRCCS Tradate 21049, Italy; giovannibattista.migliori@icsmaugeri.it (G.B.M.); rosella.centis@icsmaugeri.it (R.C.); liadambrosio59@gmail.com (L.D.)
– name: 8 Pediatric Highly Intensity Care Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan 20122, Italy
– name: 2 Department of Infectious Diseases, Galliera Hospital, Genoa 16128, Italy; pontals@yahoo.com
– name: 3 Clinical Epidemiology and Medical Statistics Unit, Department of Biomedical Sciences, University of Sassari, Sassari 07100, Italy; gsotgiu@uniss.it
– name: 4 Public Health Consulting Group, Lugano CH-6904, Switzerland
– name: 5 Division of Infection, Royal London Hospital, Barts Health NHS Trust, 80 Newark Street, London E1 2ES, UK; simon.tiberi@bartshealth.nhs.uk
– name: 7 Pediatric Clinic, Department of Surgical and Biomedical Sciences, Università degli Studi di Perugia, Perugia 06129, Italy
– name: 6 Unit of Infectious Diseases, Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna 40138, Italy; mtadolini@hotmail.com
Author_xml – sequence: 1
  givenname: Giovanni
  surname: Migliori
  fullname: Migliori, Giovanni
– sequence: 2
  givenname: Emanuele
  orcidid: 0000-0002-1085-0442
  surname: Pontali
  fullname: Pontali, Emanuele
– sequence: 3
  givenname: Giovanni
  orcidid: 0000-0002-1600-4474
  surname: Sotgiu
  fullname: Sotgiu, Giovanni
– sequence: 4
  givenname: Rosella
  surname: Centis
  fullname: Centis, Rosella
– sequence: 5
  givenname: Lia
  surname: D’Ambrosio
  fullname: D’Ambrosio, Lia
– sequence: 6
  givenname: Simon
  surname: Tiberi
  fullname: Tiberi, Simon
– sequence: 7
  givenname: Marina
  surname: Tadolini
  fullname: Tadolini, Marina
– sequence: 8
  givenname: Susanna
  orcidid: 0000-0003-4103-2837
  surname: Esposito
  fullname: Esposito, Susanna
BackLink https://www.ncbi.nlm.nih.gov/pubmed/28178199$$D View this record in MEDLINE/PubMed
BookMark eNqN0s1vFCEUAHBiauyH3jwbEi8eHAWGYcBDk7qtH0mNSd2eJzC8qWxmoAVmdf8C_22prc228eAJwvvx8uC9fbTjgweEnlPypq4VeetWU6KSMFJz-gjtUc5YRYhod7b2u2g_pRUhrGaNeoJ2maStpErtoV-LMBnnweLzBDgM-BhGPWnvLNbe4vdg9dXsxiJwDngZQWf8ZR6zs3G-qM4guZS1z3_wyc8MPrk1jBt8fD-8nA3Efh5DOXiHj_C3Tcow6ex6fAZrBz-eoseDHhM8u10P0PmHk-XiU3X69ePnxdFp1XPe5AokJa3qqTVGGc1BQE0ZkUJKagbdKmap6iUfVAvSckqppYZI0_CmMcbSoT5Ahzd5L2czge3B56jH7jK6ScdNF7Tr7ke8-95dhHXX1LyWrSgJXt0miOFqhpS7yaUexlF7CHPqqFRUCtKK5j-oEEIxrnihLx_QVZijLz9RVCs5I4Kqol5sF39X9d92FvD6BvQxpBRhuCOUdNfT0m1PS-HsAe9dLk0J1093478v_QYrlsS_
CitedBy_id crossref_primary_10_1016_j_jgar_2017_10_006
crossref_primary_10_1093_cid_ciac876
crossref_primary_10_1007_s40262_022_01133_2
crossref_primary_10_1016_j_ymthe_2017_12_016
crossref_primary_10_1111_resp_13345
crossref_primary_10_21292_2075_1230_2021_99_2_58_66
crossref_primary_10_1183_13993003_01643_2017
crossref_primary_10_1002_jcla_25091
crossref_primary_10_1128_JCM_01304_20
crossref_primary_10_1080_1120009X_2017_1338845
crossref_primary_10_1016_j_idc_2019_09_002
crossref_primary_10_1128_cmr_00180_19
crossref_primary_10_1016_j_ijid_2022_02_043
crossref_primary_10_1016_j_rppnen_2017_10_009
crossref_primary_10_1136_bmjgh_2021_007490
crossref_primary_10_1080_17476348_2017_1335599
crossref_primary_10_4236_jtr_2025_132006
crossref_primary_10_3389_fmicb_2021_717045
crossref_primary_10_1128_spectrum_01048_23
crossref_primary_10_1155_2018_1314941
crossref_primary_10_1183_13993003_02467_2017
crossref_primary_10_1016_j_ijid_2023_03_023
crossref_primary_10_1002_cpt_2685
crossref_primary_10_1016_j_jgar_2021_02_017
crossref_primary_10_1080_14656566_2020_1781091
crossref_primary_10_1089_mdr_2021_0441
crossref_primary_10_1183_13993003_01462_2017
crossref_primary_10_21292_2075_1230_2018_96_11_74_82
crossref_primary_10_1183_13993003_00146_2017
crossref_primary_10_1016_j_bjid_2022_102701
crossref_primary_10_1371_journal_pone_0196322
crossref_primary_10_1183_13993003_00017_2018
crossref_primary_10_1111_hiv_12748
crossref_primary_10_58838_2075_1230_2023_101_2_38_44
crossref_primary_10_1007_s12088_017_0674_0
Cites_doi 10.1183/09031936.00145014
10.1016/S1473-3099(16)00047-5
10.5588/ijtld.15.0962
10.1183/13993003.01297-2015
10.1183/13993003.01249-2016
10.1183/13993003.02352-2016
10.1183/13993003.01207-2016
10.1056/NEJMoa0808427
10.1183/09031936.00116011
10.1056/NEJMoa1313865
10.1183/13993003.01278-2015
10.1183/13993003.00432-2015
10.1056/NEJMoa1112433
10.1183/09031936.00135014
10.1183/13993003.02146-2015
10.1371/journal.pmed.1000097
10.1183/13993003.00705-2016
10.1056/NEJMoa1201964
10.1183/13993003.00724-2015
10.1016/S1473-3099(15)00296-0
10.1016/j.ijid.2016.10.026
10.1183/09031936.00022912
10.1183/13993003.00637-2016
10.1586/14787210.2015.1011127
10.1093/cid/ciw088
10.1183/09031936.00079413
10.1183/09031936.00204611
10.1183/13993003.congress-2016.PA1914
10.1183/09031936.00124312
10.1183/09031936.00073611
10.1183/09031936.00136312
10.1183/09031936.00060414
10.1183/09031936.00191712
10.1183/13993003.01289-2016
10.1183/13993003.01891-2015
10.1183/13993003.01552-2016
10.1183/09031936.00195210
10.1183/09031936.00125812
10.1183/09031936.00134712
ContentType Journal Article
Copyright Copyright MDPI AG 2017
2017 by the authors. 2017
Copyright_xml – notice: Copyright MDPI AG 2017
– notice: 2017 by the authors. 2017
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88E
8FI
8FJ
8FK
8G5
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
GUQSH
K9.
M0S
M1P
M2O
MBDVC
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
Q9U
7U8
7X8
C1K
JXQ
7QL
7TK
5PM
DOI 10.3390/ijms18020341
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
Research Library (Alumni Edition)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
Research Library Prep
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni Edition)
PML(ProQuest Medical Library)
Research Library
Research Library (Corporate)
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic (retired)
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
TOXLINE
MEDLINE - Academic
Environmental Sciences and Pollution Management
Toxline
Bacteriology Abstracts (Microbiology B)
Neurosciences Abstracts
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
Research Library Prep
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
Research Library (Alumni Edition)
ProQuest Central China
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
ProQuest Research Library
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Central Basic
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
TOXLINE
MEDLINE - Academic
Environmental Sciences and Pollution Management
Neurosciences Abstracts
Bacteriology Abstracts (Microbiology B)
DatabaseTitleList MEDLINE
TOXLINE

Neurosciences Abstracts
CrossRef
Publicly Available Content Database
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: PIMPY
  name: Publicly Available Content Database
  url: http://search.proquest.com/publiccontent
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1422-0067
EndPage 341
ExternalDocumentID PMC5343876
4320951893
28178199
10_3390_ijms18020341
Genre Meta-Analysis
Systematic Review
Journal Article
GroupedDBID ---
29J
2WC
53G
5GY
5VS
7X7
88E
8FE
8FG
8FH
8FI
8FJ
8G5
A8Z
AADQD
AAFWJ
AAHBH
AAYXX
ABDBF
ABUWG
ACGFO
ACIHN
ACIWK
ACPRK
ACUHS
ADBBV
ADRAZ
AEAQA
AENEX
AFFHD
AFKRA
AFZYC
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BAWUL
BCNDV
BENPR
BPHCQ
BVXVI
CCPQU
CITATION
CS3
D1I
DIK
DU5
DWQXO
E3Z
EBD
EBS
EJD
ESX
F5P
FRP
FYUFA
GNUQQ
GUQSH
GX1
HH5
HMCUK
HYE
IAO
IHR
IPNFZ
ITC
KQ8
LK8
M1P
M2O
M48
MODMG
O5R
O5S
OK1
OVT
P2P
PHGZM
PHGZT
PIMPY
PJZUB
PPXIY
PQQKQ
PROAC
PSQYO
RIG
RNS
RPM
TR2
TUS
UKHRP
~8M
ALIPV
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7XB
8FK
ESTFP
K9.
MBDVC
PKEHL
PQEST
PQUKI
PRINS
Q9U
7U8
7X8
C1K
JXQ
PUEGO
7QL
7TK
5PM
ID FETCH-LOGICAL-c445t-e81079c1dbb9ba4e6e312086881bfa792d19c84f97e8d4111d1b08b5455bbd1f3
IEDL.DBID BENPR
ISICitedReferencesCount 45
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000395457700109&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1422-0067
1661-6596
IngestDate Tue Nov 04 01:57:03 EST 2025
Tue Oct 07 09:19:55 EDT 2025
Wed Oct 01 14:01:27 EDT 2025
Mon Oct 20 02:57:06 EDT 2025
Mon Jul 21 05:21:42 EDT 2025
Sat Nov 29 07:10:29 EST 2025
Tue Nov 18 22:16:42 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords effectiveness
safety
tolerability
MDR-TB
delamanid
XDR-TB
bedaquiline
Language English
License Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c445t-e81079c1dbb9ba4e6e312086881bfa792d19c84f97e8d4111d1b08b5455bbd1f3
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
content type line 14
ObjectType-Feature-3
ObjectType-Evidence Based Healthcare-1
ObjectType-Feature-2
content type line 23
ObjectType-Review-1
ObjectType-Article-3
ObjectType-Undefined-4
ObjectType-Article-1
ORCID 0000-0002-1600-4474
0000-0003-4103-2837
0000-0002-1085-0442
OpenAccessLink https://www.proquest.com/docview/1878420619?pq-origsite=%requestingapplication%
PMID 28178199
PQID 1878420619
PQPubID 2032341
PageCount 1
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_5343876
proquest_miscellaneous_1891860765
proquest_miscellaneous_1866692494
proquest_journals_1878420619
pubmed_primary_28178199
crossref_primary_10_3390_ijms18020341
crossref_citationtrail_10_3390_ijms18020341
PublicationCentury 2000
PublicationDate 2017-02-07
PublicationDateYYYYMMDD 2017-02-07
PublicationDate_xml – month: 02
  year: 2017
  text: 2017-02-07
  day: 07
PublicationDecade 2010
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
– name: Basel
PublicationTitle International journal of molecular sciences
PublicationTitleAlternate Int J Mol Sci
PublicationYear 2017
Publisher MDPI AG
MDPI
Publisher_xml – name: MDPI AG
– name: MDPI
References Tiberi (ref_40) 2016; 47
Esposito (ref_21) 2014; 44
ref_14
ref_13
ref_12
Sotgiu (ref_10) 2016; 48
Sotgiu (ref_33) 2013; 42
Rioux (ref_43) 2016; 16
Tadolini (ref_20) 2016; 48
ref_18
ref_17
ref_16
ref_15
Diel (ref_6) 2014; 43
Sotgiu (ref_19) 2015; 13
Falzon (ref_11) 2011; 38
ref_24
Falzon (ref_3) 2013; 42
ref_28
Diacon (ref_25) 2009; 360
ref_27
Sotgiu (ref_35) 2015; 45
Sotgiu (ref_29) 2015; 45
Diel (ref_5) 2012; 40
Bonnet (ref_47) 2016; 20
Migliori (ref_8) 2007; 12
Villar (ref_30) 2011; 38
Lee (ref_34) 2012; 367
Sotgiu (ref_32) 2012; 40
Migliori (ref_4) 2013; 42
Tadolini (ref_44) 2016; 48
Alffenaar (ref_36) 2013; 41
ref_39
ref_38
ref_46
ref_45
Centis (ref_31) 2012; 39
ref_42
ref_1
Skripconoka (ref_22) 2013; 41
ref_2
ref_49
ref_48
Tiberi (ref_37) 2016; 47
Diacon (ref_26) 2014; 371
Caminero (ref_9) 2015; 46
Gler (ref_23) 2012; 366
ref_7
Matteelli (ref_41) 2015; 15
References_xml – volume: 45
  start-page: 25
  year: 2015
  ident: ref_29
  article-title: Linezolid to treat MDR-/XDR-Tuberculosis: Available evidence and future scenarios
  publication-title: Eur. Respir. J.
  doi: 10.1183/09031936.00145014
– volume: 16
  start-page: 294
  year: 2016
  ident: ref_43
  article-title: Bedaquiline plus delamanid for XDR tuberculosis
  publication-title: Lancet. Infect. Dis.
  doi: 10.1016/S1473-3099(16)00047-5
– volume: 20
  start-page: 177
  year: 2016
  ident: ref_47
  article-title: Identification of patients who could benefit from bedaquiline or delamanid: A multisite MDR-TB cohort study
  publication-title: Int. J. Tuberc. Lung Dis.
  doi: 10.5588/ijtld.15.0962
– ident: ref_49
– ident: ref_16
– ident: ref_2
  doi: 10.1183/13993003.01297-2015
– ident: ref_1
– volume: 48
  start-page: 1503
  year: 2016
  ident: ref_10
  article-title: Faster for less, the new “Shorter” regimen for multidrug-resistant tuberculosis
  publication-title: Eur. Respir. J.
  doi: 10.1183/13993003.01249-2016
– ident: ref_28
  doi: 10.1183/13993003.02352-2016
– ident: ref_46
  doi: 10.1183/13993003.01207-2016
– volume: 360
  start-page: 2397
  year: 2009
  ident: ref_25
  article-title: The diarylquinoline TMC207 for multidrug-resistant tuberculosis
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa0808427
– volume: 39
  start-page: 770
  year: 2012
  ident: ref_31
  article-title: On linezolid efficacy and tolerability
  publication-title: Eur. Respir. J.
  doi: 10.1183/09031936.00116011
– ident: ref_27
– volume: 371
  start-page: 723
  year: 2014
  ident: ref_26
  article-title: Multidrug-resistant tuberculosis and culture conversion with bedaquiline
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1313865
– ident: ref_48
– volume: 47
  start-page: 333
  year: 2016
  ident: ref_40
  article-title: Migliori, G.B. Ertapenem in the treatment of multidrug-resistant tuberculosis: First clinical experience
  publication-title: Eur. Respir. J.
  doi: 10.1183/13993003.01278-2015
– volume: 46
  start-page: 887
  year: 2015
  ident: ref_9
  article-title: Classification of antituberculosis drugs: A new proposal based on the most recent evidence
  publication-title: Eur. Respir. J.
  doi: 10.1183/13993003.00432-2015
– volume: 366
  start-page: 2151
  year: 2012
  ident: ref_23
  article-title: Delamanid for multidrug-resistant pulmonary tuberculosis
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1112433
– volume: 45
  start-page: 287
  year: 2015
  ident: ref_35
  article-title: Low minimal inhibitory concentrations of linezolid against multidrug-resistant tuberculosis strains
  publication-title: Eur. Respir. J.
  doi: 10.1183/09031936.00135014
– volume: 47
  start-page: 1235
  year: 2016
  ident: ref_37
  article-title: Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of multidrug and extensively drug-resistant tuberculosis
  publication-title: Eur. Respir. J.
  doi: 10.1183/13993003.02146-2015
– ident: ref_42
  doi: 10.1371/journal.pmed.1000097
– volume: 48
  start-page: 938
  year: 2016
  ident: ref_20
  article-title: Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively-drug resistant tuberculosis: Early experiences and challenges
  publication-title: Eur. Respir. J.
  doi: 10.1183/13993003.00705-2016
– ident: ref_17
– volume: 367
  start-page: 1508
  year: 2012
  ident: ref_34
  article-title: Linezolid for treatment of chronic extensively drug-resistant tuberculosis
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1201964
– ident: ref_24
  doi: 10.1183/13993003.00724-2015
– volume: 15
  start-page: 1131
  year: 2015
  ident: ref_41
  article-title: Compassionate and optimum use of new tuberculosis drugs
  publication-title: Lancet. Infect. Dis.
  doi: 10.1016/S1473-3099(15)00296-0
– ident: ref_12
  doi: 10.1016/j.ijid.2016.10.026
– ident: ref_7
– volume: 40
  start-page: 1430
  year: 2012
  ident: ref_32
  article-title: Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: Systematic review and meta-analysis
  publication-title: Eur. Respir. J.
  doi: 10.1183/09031936.00022912
– volume: 48
  start-page: 935
  year: 2016
  ident: ref_44
  article-title: First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline
  publication-title: Eur. Respir. J.
  doi: 10.1183/13993003.00637-2016
– volume: 13
  start-page: 305
  year: 2015
  ident: ref_19
  article-title: Delamanid (OPC-67683) for treatment of multi-drug-resistant tuberculosis
  publication-title: Expert Rev. Anti Infect. Ther.
  doi: 10.1586/14787210.2015.1011127
– ident: ref_38
  doi: 10.1093/cid/ciw088
– volume: 43
  start-page: 554
  year: 2014
  ident: ref_6
  article-title: Costs of tuberculosis disease in the European Union: A systematic analysis and cost calculation
  publication-title: Eur. Respir. J.
  doi: 10.1183/09031936.00079413
– ident: ref_14
– volume: 40
  start-page: 143
  year: 2012
  ident: ref_5
  article-title: Tuberculosis: Cost of illness in Germany
  publication-title: Eur. Respir. J.
  doi: 10.1183/09031936.00204611
– ident: ref_39
  doi: 10.1183/13993003.congress-2016.PA1914
– volume: 41
  start-page: 1386
  year: 2013
  ident: ref_36
  article-title: Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB
  publication-title: Eur. Respir. J.
  doi: 10.1183/09031936.00124312
– volume: 12
  start-page: E070517.1
  year: 2007
  ident: ref_8
  article-title: First tuberculosis cases in Italy resistant to all tested drugs
  publication-title: Euro Surveill.
– volume: 38
  start-page: 516
  year: 2011
  ident: ref_11
  article-title: WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update
  publication-title: Eur. Respir. J.
  doi: 10.1183/09031936.00073611
– volume: 42
  start-page: 169
  year: 2013
  ident: ref_4
  article-title: Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB. Drug resistance beyond extensively drug-resistant tuberculosis: Individual patient data meta-analysis
  publication-title: Eur. Respir. J.
  doi: 10.1183/09031936.00136312
– volume: 44
  start-page: 811
  year: 2014
  ident: ref_21
  article-title: ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: Case study of compassionate delamanid use
  publication-title: Eur. Respir. J.
  doi: 10.1183/09031936.00060414
– volume: 42
  start-page: 288
  year: 2013
  ident: ref_33
  article-title: International Group for the study of Linezolid. Linezolid to treat extensively drug-resistant TB: Retrospective data are confirmed by experimental evidence
  publication-title: Eur. Respir. J.
  doi: 10.1183/09031936.00191712
– ident: ref_13
  doi: 10.1183/13993003.01289-2016
– ident: ref_18
  doi: 10.1183/13993003.01891-2015
– ident: ref_45
  doi: 10.1183/13993003.01552-2016
– ident: ref_15
– volume: 38
  start-page: 730
  year: 2011
  ident: ref_30
  article-title: Linezolid safety, tolerability and efficacy to treat multidrug- and extensively drug-resistant tuberculosis
  publication-title: Eur. Respir. J.
  doi: 10.1183/09031936.00195210
– volume: 41
  start-page: 1393
  year: 2013
  ident: ref_22
  article-title: Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis
  publication-title: Eur. Respir. J.
  doi: 10.1183/09031936.00125812
– volume: 42
  start-page: 156
  year: 2013
  ident: ref_3
  article-title: Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB. Resistance to fluoroquinolones and second-line injectable drugs: Impact on multidrug-resistant TB outcomes
  publication-title: Eur. Respir. J.
  doi: 10.1183/09031936.00134712
SSID ssj0023259
Score 2.3935254
SecondaryResourceType review_article
Snippet The new drugs delamanid and bedaquiline are increasingly being used to treat multidrug-resistant (MDR-) and extensively drug-resistant tuberculosis (XDR-TB)....
SourceID pubmedcentral
proquest
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 341
SubjectTerms Antitubercular Agents - therapeutic use
Diarylquinolines - administration & dosage
Diarylquinolines - adverse effects
Diarylquinolines - therapeutic use
Drug resistance
Drug Therapy, Combination
Extensively Drug-Resistant Tuberculosis - diagnosis
Extensively Drug-Resistant Tuberculosis - drug therapy
Extensively Drug-Resistant Tuberculosis - epidemiology
Extensively Drug-Resistant Tuberculosis - microbiology
Humans
Multidrug resistant organisms
Mycobacterium
Nitroimidazoles - administration & dosage
Nitroimidazoles - adverse effects
Nitroimidazoles - therapeutic use
Oxazoles - administration & dosage
Oxazoles - adverse effects
Oxazoles - therapeutic use
Review
Studies
Treatment Outcome
Tuberculosis
Tuberculosis, Multidrug-Resistant - diagnosis
Tuberculosis, Multidrug-Resistant - drug therapy
Tuberculosis, Multidrug-Resistant - epidemiology
Tuberculosis, Multidrug-Resistant - microbiology
Title Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review
URI https://www.ncbi.nlm.nih.gov/pubmed/28178199
https://www.proquest.com/docview/1878420619
https://www.proquest.com/docview/1866692494
https://www.proquest.com/docview/1891860765
https://pubmed.ncbi.nlm.nih.gov/PMC5343876
Volume 18
WOSCitedRecordID wos000395457700109&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVPQU
  databaseName: Health & Medical Collection
  customDbUrl:
  eissn: 1422-0067
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0023259
  issn: 1422-0067
  databaseCode: 7X7
  dateStart: 20000301
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl:
  eissn: 1422-0067
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0023259
  issn: 1422-0067
  databaseCode: BENPR
  dateStart: 20000301
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Publicly Available Content Database
  customDbUrl:
  eissn: 1422-0067
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0023259
  issn: 1422-0067
  databaseCode: PIMPY
  dateStart: 20000301
  isFulltext: true
  titleUrlDefault: http://search.proquest.com/publiccontent
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Research Library
  customDbUrl:
  eissn: 1422-0067
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0023259
  issn: 1422-0067
  databaseCode: M2O
  dateStart: 20000301
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/pqrl
  providerName: ProQuest
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB7RLUhceD8WSmUkOKGoG9uJbS6opVvBocuqbKXltLJjB4KWpN0kiP4C_jbjJBu6IHrhEsnxSLE045nvsyczAC9SalXsTBqMlEaCEhseaB2bILYm4txGHoI3zSbEZCLnczXtDtzKLq1y7RMbR22LxJ-R74VSSE4x-qg3Z-eB7xrlb1e7FhpbsO0rlfEBbB-MJ9OTnnIx2rRLCzEKBXGk4jb1nSHR38u-fit9-bMR4-FmUPoLaf6ZMHkpAh3d_t-134FbHfYk-62x3IVrLr8HN9pulBf34Sf6BuTJzpLT0pEiJYcOzUXnmSU6t-TAWX1eZx6WkqogM482SfP_rl3Vn4MTV3oomleN8PhHlxm_vCCHm9Oz2rhVUi8LfPGa7JOPfS1p0l5UPIDTo_Hs7bug69MQJJxHVeAkckiVhNYYZTR3sWMhRaokERKnWihqQ5VInirhpOXoXG1oRhJtIYqMsWHKHsIgL3L3GIhu6v1oyVzKuUeXjirObMKsSlJD5RBerRW1SLoi5r6XxnKBZMardXFZrUN42UuftcU7_iG3s9bbotvC5eK30obwvJ_GzedvVHTuitrLIPvzDJZfJaNQbCTiaAiPWjPqF0NlKBCS4RfEhoH1Ar749-ZMnn1pioBHjDOMZE-uXvpTuEk9DvFp5mIHBtWqds_gevK9ysrVLmyJuWiecrfbOTg6ph9wNH1_PP30C44eJkE
linkProvider ProQuest
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3bbtQwELVKAcEL98tCASPRJxQ1sZ3YRkKosK1atawQbKV9C3bstIuWpN0kwH4Bf8M3Ms6tXRB96wOv8VFiJcczZ-LxDEIvUmJkZHXq-VJBgBJp5ikVaS8yOmTMhE6C180m-GgkJhP5YQX96s7CuLTKzibWhtrkiftHvhEILhgB7yPfHJ94rmuU213tWmg0tNizi-8QshWvd4fwfdcJ2d4av9vx2q4CXsJYWHpWQMQjk8BoLbViNrI0ICDsBQi4VHFJTCATwVLJrTAMTIEJtC9g5mGotQlSCve9hC6DHecuhYxPTgM8SurmbAH4PC8KZdQk2lMq_Y3pl6-FK7bmUxYsu8C_dO2f6Zln_N32zf_tTd1CN1pljTebpXAbrdjsDrra9Npc3EU_wfJpkNQGHxQW5ykeWlgMKpsarDKD31qjTqqpE924zPHYaWlcn0428-rQ-2gLJ7SzsgZv_Wjz_mcLPFweHlfazpNqlsOFV3gTf-orZeNmG-YeOriQt3AfrWZ5Zh8irOpqRkpQmzLmtLMlklGTUCOTVBMxQC87YsRJW6LddQqZxRCqORrFZ2k0QOs9-rgpTfIP3FrHk7g1UEV8SpIBet4Pg2lx-0Uqs3nlMBDbuvicnYeRAPN5FA7Qg4a2_WSICDgITngCXyJ0D3ClzZdHsulRXeI8pIyCn350_tSfoWs74_f78f7uaO8xuk6c4nIJ9XwNrZbzyj5BV5Jv5bSYP63XKUafL5ruvwElLH0d
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwELZKC4gL78dCASPRE4o2sZ3ERkKoZXdFVbRala3UW7BjB4KWpN0kwP4C_hO_jnFedEH01gPXeJQ4zjcz38TjGYSeJ0SLwKjEcYWEACVQzJEyUE6glc-Y9i0Fr5tNhNMpPz4Wsw30szsLY9MqO5tYG2qdx_Yf-dDjIWcEvI8YJm1axGw0eX1y6tgOUnantWun0UDkwKy-QfhWvNofwbfeIWQynr9567QdBpyYMb90DIfoR8SeVkooyUxgqEeA5HMgc4kMBdGeiDlLRGi4ZmAWtKdcDm_h-0ppL6Fw30toKwSSAdq1tTeezg77cI-SulWbBx7QCXwRNGn3lAp3mH7-UtjSay5l3rpD_Ivl_pmsecb7TW78z-t2E11vOTfebZTkFtow2W10penCubqDfoBNVEC2NT4qDM4TPDKgJjJLNZaZxntGy9MqtXQclzmeW5aN63PLell9dA5NYSl4VtbC4-_tiYDFCo_Wh-eVMsu4WuRw4SXexe_7Gtq42aC5i44uZBXuoc0sz8wDhGVd50hyahLGLKs2RDCqY6pFnCjCB-hFB5Iobou32x4iiwiCOAup6CykBminlz5pipb8Q267w0zUmq4i-g2YAXrWD4PRsTtJMjN5ZWUg6rWROztPRoCYGwb-AN1vINxPhnAvBCoKTwjXwN0L2KLn6yNZ-qkufu5TRsGDPzx_6k_RVUB59G5_evAIXSOWitlM-3AbbZbLyjxGl-OvZVosn7RKi9GHi8b7L61qhz4
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Combined+Use+of+Delamanid+and+Bedaquiline+to+Treat+Multidrug-Resistant+and+Extensively+Drug-Resistant+Tuberculosis%3A+A+Systematic+Review&rft.jtitle=International+journal+of+molecular+sciences&rft.au=Migliori%2C+Giovanni+Battista&rft.au=Pontali%2C+Emanuele&rft.au=Sotgiu%2C+Giovanni&rft.au=Centis%2C+Rosella&rft.date=2017-02-07&rft.pub=MDPI+AG&rft.issn=1661-6596&rft.eissn=1422-0067&rft.volume=18&rft.issue=2&rft.spage=341&rft_id=info:doi/10.3390%2Fijms18020341&rft.externalDBID=HAS_PDF_LINK&rft.externalDocID=4320951893
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1422-0067&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1422-0067&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1422-0067&client=summon